ClinicalTrials.gg
RecruitingNCT06809868SITEUpdated Jan 30, 2026

Role of Transposable Elements in Septic Immune Aging

An observational study in Sepsis, Sepsis and Septic Shock and Sepsis With Multiple Organ Dysfunction (MOD), sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-30.

Primary conditionShock, SepticRegistry: SepsisReclassifiedWhy we changed it
Registry
Sepsis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Shock, Septic
Why
  1. The study's listed conditions name Shock, Septic, a narrower term within Sepsis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of California, San Francisco · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
116
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 164 studies in Shock, Septic with a site in United States — 18 open to participants now, 26 under way, 1 of them phase 3. Shock, Septic · United States.

Planned enrollment
32nd of 47
116 · median 330
Started
2025
with 4 others
Observational
47 of 164
6 open now
Primary completion
2028-02
later than 21 of 25 live
Registered
156th of 164
by date

Among the 164 studies in Shock, Septic with a site in United States, this one is the 32nd largest by planned enrollment of the 47 observational ones that give a count, is one of 5 that started in 2025, is one of 47 observational ones, reaches primary completion later than 21 of the 25 other live ones, and was the 156th registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

18 of the 164 studies in Shock, Septic with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Shock, Septic with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about how transposable element levels affect the patient outcomes in sepsis. The main questions it aims to answer is:

  1. Do transposable elements prematurely age the immune systems of patients with sepsis?
  2. Do transposable elements correlate with increased mortality in patients with sepsis in the ICU?
  3. Do transposable elements correlate with increased amount of secondary infections in patients with sepsis in the ICU?

Participants will have blood drawn from them but will not be subjected to additional interventions.

03

Conditions studied

  • Sepsis
  • Sepsis and Septic Shock
  • Sepsis With Multiple Organ Dysfunction (MOD)
  • Sepsis With Acute Organ Dysfunction
  • Sepsis, Severe
  • Sepsis at Intensive Care Unit
  • Sepsis, Severe Sepsis and Septic Shock
  • Sepsis, Septic Shock

Browse trials for

Keywords

  • Sepsis
  • Transposable Elements
  • Immune Aging
  • Mortality
  • Secondary Infections
  • Critical Care Medicine (ICU)
04

In context

Shock, Septic Reclassified

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

This study's planned enrollment of 116 is close to the median of 108 across 408 observational studies indexed under Shock, Septic.

Browse Shock, Septic studies →

Lead sponsor

University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.

Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.

Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population includes adult patients admitted to the intensive care unit with sepsis with a SOFA score of at least 2. Sepsis is defined by the Sepsis 3 Criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or older
  • Admitted to ICU with sepsis (Sepsis 3 Criteria)
  • SOFA score of at least 2 at time of enrollment

Exclusion criteria

Exclusion Criteria:

  • Patients on organ transplantation
  • Patients with preexisting leukopenia
  • Cancer patients receiving CAR-T therapy
  • Patients who are under 18 years of age or otherwise deemed pediatric
  • Patients with an ongoing bleeding diathesis (ie: DIC, hemorrhagic shock)
  • Patients with a chronic below 7.0
  • Patients who, prior to their ICU admission, are blood transfusion dependent
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
116 participants (estimated)
Target follow-up
6 Weeks
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with Sepsis

    Adult patients (age 18 and older) admitted to the intensive care unit (ICU) meeting Sepsis 3 Criteria.

    Genetic: RNA and DNA Sequencing

  • Healthy Individual Controls

    Healthy individuals not admitted to the hospital.

    Genetic: RNA and DNA Sequencing

Interventions

  • GeneticRNA and DNA Sequencing

    DNA and RNA sequencing will be conducted on both control participants and patients with sepsis who are admitted to the ICU.

07

What researchers measure

Primary outcomes

  1. Immune Aging

    Time frame: 6 weeks

Secondary outcomes

  1. Mortality (30-day)

    Time frame: 30 days

  2. Secondary Infection

    Time frame: 30 days

08

Study locations

1 of 1 sites recruiting
  • University of California, San Francisco
    San Francisco, California 94143, United States
    Recruiting
    • Alexendar R Perez, M.D., Ph.D · ContactAlexendar.Perez@ucsf.edu · 415-476-1000
    • Matthieu Legrand, M.D., Ph.D · Contactmatthieu.legrand@ucsf.edu · 415-476-1000
    • Alexendar R Perez, M.D., Ph.D · Principal investigator
    • Judith Hellman, M.D. · Principal investigator
    • Matthieu Legrand, M.D., Ph.D · Principal investigator
    • Elizabeth Whitlock, M.D. · Sub investigator
    • Orestes Mavrothalassitis, M.D. · Sub investigator
    • Joana Vidigal, Ph.D · Sub investigator
09

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2028, 36 months after the start.

Of 189 non-industry observational studies under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 47. This study's planned 36 months is above that.

Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2025
First posted
Feb 5, 2025
StartActual
Feb 14, 2025
Primary completionEst.
Feb 14, 2028
CompletionEst.
Aug 14, 2028
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06809868
Responsible party
Sponsor
First posted
Feb 5, 2025
Start date
Feb 14, 2025
Primary completion
Feb 14, 2028 (estimated)
Completion
Aug 14, 2028 (estimated)
Last update
Jan 30, 2026

Study contacts

Alexendar R Perez, M.D., Ph.D
Contact
Alexendar.Perez@ucsf.edu
415-476-1000
Matthieu Legrand, M.D., Ph.D
Contact
matthieu.legrand@ucsf.edu
415-476-1000
Alexendar R Perez, M.D., Ph.D
principal investigator · University of California, San Francisco
Judith Hellman, M.D.
principal investigator · University of California, San Francisco
Matthieu Legrand, M.D., Ph.D
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion